New Hepatitis C Guidelines
(AASLD, IDSA, IAS-USA)
Dr. Ahsan
MBBS,FCPS (Medicine)
Senior Registrar Medical Unit-1
• The Evidence based consensus
recommendations for the screening, treatment
and management of patients with HCV were
devel...
Types of Recommendations
• "Recommended”: when regimen is favored for
most patients
• "Alternative" when optimal in a part...
IFN ineligible
IFN ineligible is defined as one or more of the below:
• Intolerance to IFN
• Autoimmune hepatitis and othe...
SOFOSBUVIR
• Sofosbuvir (Tab. Sovaldi 400mg) is a prodrug
of a nucleotide analogue inhibitor of the HCV
NS5B RNA-dependent...
SIMEPREVIR
• Simeprevir (150 mg daily), a specific inhibitor
of the HCV NS3/4A serine protease.
• COSMOS TRIAL: GENOTYPE 1
Genotype 3 Recommendations
• It is anticipated that safer and more effective
IFN-free regimens will be available by 2015.
Hepatitis c new guidelines 2014 by aasld idsa sofosbuvir
Upcoming SlideShare
Loading in …5
×

Hepatitis c new guidelines 2014 by aasld idsa sofosbuvir

3,061 views

Published on

hcv guidelines 2014 sofosbuvir aasld idsa

Published in: Health & Medicine
0 Comments
5 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
3,061
On SlideShare
0
From Embeds
0
Number of Embeds
7
Actions
Shares
0
Downloads
208
Comments
0
Likes
5
Embeds 0
No embeds

No notes for slide

Hepatitis c new guidelines 2014 by aasld idsa sofosbuvir

  1. 1. New Hepatitis C Guidelines (AASLD, IDSA, IAS-USA) Dr. Ahsan MBBS,FCPS (Medicine) Senior Registrar Medical Unit-1
  2. 2. • The Evidence based consensus recommendations for the screening, treatment and management of patients with HCV were developed by a panel of 27 liver disease and infectious disease specialists and a patient advocate. • Available Online on; • www.hcvguidelines.org
  3. 3. Types of Recommendations • "Recommended”: when regimen is favored for most patients • "Alternative" when optimal in a particular subset of patients in that category. • "Not Recommended" When a treatment is clearly inferior or is deemed harmful, such regimens should not be administered to patients with HCV infection
  4. 4. IFN ineligible IFN ineligible is defined as one or more of the below: • Intolerance to IFN • Autoimmune hepatitis and other autoimmune disorders • Hypersensitivity to PEG or any of its components • Decompensated hepatic disease • History of depression, or clinical features consistent with depression • A baseline neutrophil count below 1500/μL, a baseline platelet count below 90,000/μL or baseline hemoglobin below 10 g/dL • A history of preexisting cardiac disease
  5. 5. SOFOSBUVIR • Sofosbuvir (Tab. Sovaldi 400mg) is a prodrug of a nucleotide analogue inhibitor of the HCV NS5B RNA-dependent RNA polymerase. • NEUTRINO, COSMOS trial: Genotype 1,4 • VALENCE , POSITRON, FISSION, FUSION, PROTON , ELECTRON : Genotype 2,3 • Approved By FDA In DEC 2013.
  6. 6. SIMEPREVIR • Simeprevir (150 mg daily), a specific inhibitor of the HCV NS3/4A serine protease. • COSMOS TRIAL: GENOTYPE 1
  7. 7. Genotype 3 Recommendations
  8. 8. • It is anticipated that safer and more effective IFN-free regimens will be available by 2015.

×